Tenderwize
Back to tender search

Open-house drug rebate agreements: Tolterodine

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Apr 30, 2027 · 161 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tolterodin, ATC G04BD07

54/100

Opportunity Score

Needs reviewHigh complexity
SuppliesOpen
Why this score?

Opportunity

54 / 100

Complexity

67 / 100

Risk factors

The buyer may introduce exclusive rebate agreements during the term, and the open-house contracts may then terminate au...

No value, volume, reimbursement or demand information is available, so expected revenue and operational scale cannot be...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Apr 30, 2027

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements under Sections 130a(8) and 130c(1) SGB V for Tolterodine medicines, ATC G04BD07.
  • Contract period is scheduled from 1 July 2025 to 30 June 2027, with individual accessions possible on the first day of each month.
Show full summary

Open-house, non-exclusive pharmaceutical rebate agreements for Tolterodine (ATC G04BD07) offered by AOK Rheinland-Pfalz/Saarland to pharmaceutical companies. There is no competitive selection decision and all participants receive uniform contractual conditions. Contracts may be concluded monthly through the maximum 24-month period, but can end automatically if replaced by exclusive agreements. Contract documents were not provided for analysis; the available notice states that they must be requested through the restricted DTVP project area.

Risks

The buyer may introduce exclusive rebate agreements during the term, and the open-house contracts may then terminate au...

No value, volume, reimbursement or demand information is available, so expected revenue and operational scale cannot be...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only pharmaceutical companies may participate.
  • Medicines must be authorised and marketable in Germany.
  • If the medicine is listed as marketable in the Lauer-Taxe, that listing serves as proof.

Buyer

Lots (1)

LOT-0001

Tolterodine Pharmaceutical Rebate Agreements

Non-exclusive rebate agreements for medicines containing Tolterodine, ATC G04BD07, under an open-house model. Children’s medicines listed under the relevant BfArM list are excluded. Contracts are available to all qualifying pharmaceutical companies under identical, non-negotiable conditions and may run for up to 24 months.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Jun 2025 - Jun 2027

Category

Pharmaceutical products

Deadline

Deadline Apr 30, 2027

Procurement Details

Publication date
18 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
320047-2025

Documents (1)

Similar tenders

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy